• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Vaccine created from patient white blood cells to target brain tumors

Vaccine created from patient white blood cells to target brain tumors

July 27, 2012
CenterWatch Staff

Researchers at Northwestern Brain Tumor Institute (NBTI) are seeking to understand if a vaccine made from a patient's own blood cells may slow the growth of glioblastoma multiformes (GBM), the most common and aggressive type of primary brain tumor.

"Glioblastomas are complicated to treat because they are aggressive, fast-growing tumors that are often resistant to standard treatment," said principal investigator James Chandler, M.D., co-director of the NBTI and surgical director of neuro-oncology at Northwestern Memorial Hospital. "In this trial, a vaccine is made using the person's own white blood cells, which we hope will have the power to stimulate an immune response to kill brain tumor cells."

The vaccine, called ICT-107, is created by collecting the participant's white blood cells through a process called apheresis, which separates the components in the blood. The white blood cells are then treated to recognize the tumor cells turning them into immune cells, which early research indicates may be able to recognize and attack the tumor cells. Patients receive the vaccine in addition to standard treatment.

The phase II trial will examine both safety and efficacy of the ICT-107 vaccine. Researchers seek to enroll approximately 225 participants nationally who are newly diagnosed with a GBM. To be considered for enrollment, a person must be 18 years or older and not have a recurrent disease or any other active malignancy or history of malignancy. They must have undergone surgery to excise the GBM, but have not yet started chemotherapy or radiation. Full inclusion and exclusion criteria can be found on ClinicalTrials.gov.

"GBMs are a devastating diagnosis and these patients unfortunately are not given a great deal of time," said Chandler. "Our goal at Northwestern Brain Tumor Institute is to provide patients with the best options to treat their cancer in a manner that not only gives them longer lives, but also improved quality of life."

The trial is an example of a growing trend in cancer research that seeks to understand if vaccines can be used to turn a person's own immune system into a weapon against cancers by slowing the growth of tumors.

Upcoming Events

  • 17May

    Three Data Trends to Consider Now When Developing Your Decentralized Clinical Trial Strategy

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing